India’s IVF market is a well-documented growth story. Yet, for all the capital flowing into premium urban chains, a fundamental geographic asymmetry remains. The investment thesis for 2026 isn’t about another metro clinic; it’s about systematically addressing the most profound penetration gap in Indian healthcare.
The Map of Mispriced Opportunity
India performs an estimated 300,000–350,000 IVF cycles annually. Conservative models place potential demand at over 1 million. This gap isn’t evenly distributed. While the West and South have seen a proliferation of organised chains like Nova IVI, Birla Fertility, and Indira IVF, the eastern corridor of Odisha, West Bengal, Jharkhand, and Bihar, home to over 250 million people, hosts fewer than a dozen organised IVF centres. This isn’t an oversight; it’s a structural challenge.
Traditional chains followed the premium urban patient westward. The eastern market, with its lower average disposable income, higher cultural stigma, and fragmented healthcare infrastructure, was deemed ‘too hard.’ The result is a supply vacuum. We estimate the addressable market in this region alone at ₹2,500–3,000 crore, growing at 18–22% CAGR, with penetration rates at less than one-third of the national average.
Why Now? The Regulatory Catalyst
For years, investor hesitation was underpinned by regulatory ambiguity. The ART (Regulation) Act 2021 and its subsequent rules have changed the game. It provides a clear framework for accreditation, data privacy, and ethical practice that institutional capital requires.
The act effectively professionalises the sector, crowding out unregulated, substandard practices and creating a runway for compliant, scalable platforms. The window for first-mover advantage in this newly formalised eastern market is open, but it is closing.
The Unit Economics of Empathy and Technology
Critics will cite lower average revenue per cycle (ARPUC) in tier-2 and tier-3 markets. This is a surface-level analysis. The real metric is EBITDA per cycle at maturity, and this is where a differentiated model creates value. A standard urban IVF clinic might achieve 35–45% EBITDA margins.
Santaan’s model, built for the eastern geography, attacks the cost structure differently:
• Tech-Enabled Patient Funnel: A telemedicine-first consultation layer reduces the cost of patient acquisition (CAC) by over 40% compared to pure digital marketing in a low-trust environment.
• Centralised Lab & AI Protocol: By centralising complex embryology for a cluster of spoke clinics and employing AI for embryo selection, we standardise the highest-cost, highest-variability component of care. This improves success rates while reducing the marginal cost of adding a new location.
• Empathy as Infrastructure: We deploy community health workers for awareness and trust-building. This isn’t philanthropy; it’s a scalable patient acquisition and retention channel that reduces long-term marketing spend and builds brand equity competitors cannot buy.
This combination, lower CAC, standardised high-cost procedures, and higher lifetime value through trust, allows us to project mature-unit EBITDA margins that are competitive with urban models, despite a lower ARPUC.
The Moat: More Than Just Geography
First-mover advantage is not just about planting a flag. It’s about building infrastructure that cannot be replicated overnight.
• The Odisha Research Institute: Established in March 2023, this isn’t a branding exercise. It generates proprietary clinical data on patient phenotypes specific to eastern India, feeding directly back into our AI models and treatment protocols. This creates a self-reinforcing loop of improved outcomes.
• Local Talent Pipeline: We are training embryologists and clinicians within the region, solving the critical talent scarcity that has stalled other chains.
• Brand as Trust: In markets where healthcare decisions are community-driven, being the first trusted, organised brand is a profound and lasting advantage.
A Founder’s Perspective: Why This, Why Here, Why Now
The following is adapted from notes by our founding team.’We didn’t start in the East because it was easy. We started here because the need was greatest and the existing solutions were the least adequate.
We’ve learned that ‘affordability’ isn’t just about price; it’s about reducing the total cost of hope, travel, uncertainty, and the feeling of being an assembly-line patient.
The challenge is real: patient education takes time. Lab accreditation is rigorous. But the path is clear. The ART Act gives us the rulebook.
Our technology gives us efficiency. And the communities we serve give us the purpose. We are building the clinical and operational proof points that this model works, not in theory, but in Bhubaneswar, and soon, beyond.’
The Ask and the Opportunity
Santaan is positioned at the intersection of three powerful trends: the formalisation of the ART sector, the digitisation of tier-2 healthcare delivery, and the unlocking of non-metro consumption. We are seeking partners who understand that the next wave of healthcare value creation in India will come from scaling quality, not just scaling premium.
The blueprint is drawn. The initial clinic and research institute are operational. The opportunity is to co-build the definitive fertility platform for the next 100 million aspirational households. The geography is defined. The time is now.